Recent Posts

Pages: 1 ... 6 7 [8] 9 10
71

From New England Journal of Medicine Catalyst (October 30, 2025)--"HealthLocator: A Public, Digital Tool for Navigating Quality Care Choices":


https://catalyst.nejm.org/doi/full/10.1056/CAT.25.0296?query=CON


This looks as if it might be useful. Its Website:


https://www.healthlocator.org/
72
MISCELLANEOUS / 12 free Medicare services
« Last post by agate on November 07, 2025, 08:59:54 pm »
From AARP (October 17,  2025):

12 Free Medicare Services
73
THE PRACTICAL SIDE OF BEING MULTIPLY SCLEROSED / MSAA MRI Access Program returns
« Last post by agate on November 06, 2025, 09:33:29 pm »
This program had been discontinued for quite a while but has recently returned.

From the MSAA (November 3, 2025):
MSAA MRI Access Program
74
NEWS / (PBS News 38-minute video) Key takeaways from the 2025 elections
« Last post by agate on November 05, 2025, 09:19:54 pm »

From PBS News (November 5, 2025): 

Key Takeaways from the 2025 Elections
75
From PubMed (November 4, 2025)--"The impact of early-life stress on patient-reported outcomes in multiple sclerosis":


https://pubmed.ncbi.nlm.nih.gov/41180902/


NOTE: Access to the entire article can be obtained by clicking on the DOI link in the abstract.
76

From PR Newswire (November 3, 2025):

Chronic Progressive Multiple Sclerosis Market to Witness Accelerated Expansion during the Forecast Period (2025-2034) Due to Strong Pipeline and Advanced Therapeutic Strategies

7MM = 7 major markets (US, Germany, France, Italy, Spain, UK, Japan)
CAGR = Compound Annual Growth Rate

"Chronic progressive MS" seems to mean both PPMS and SPMS, as differentiated from RRMS here.
77
From BBC.com (October 25, 2005):

How Daylight Saving Time Affects Your Health
78
MISCELLANEOUS / Updated evidence for COVID-19, RSV, and influenza vaccines for 2025-2026
« Last post by agate on November 01, 2025, 09:02:52 pm »
From New England Journal of Medicine (October 29, 2025):

Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026
80
TREATMENTS / (Abst.) Moderate-high efficacy DMTs reduce relapse risk in late-onset MS
« Last post by agate on October 30, 2025, 09:01:04 pm »
From PubMed (October 30, 2025)--"Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis":


https://pubmed.ncbi.nlm.nih.gov/41161724/
Pages: 1 ... 6 7 [8] 9 10